New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Ask the Heart Doctor | Heart Valve Disease and Sur...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
Mark Cuban: A Master Disrupter for American Health...
Teen girls facing the most adversity showed the biggest gain...
September 15,2026
Specialized imaging reveals hormone-driven brain changes...
September 14,2026
Submillimeter MRI reveals brain hubs that guide risky decisi...
September 12,2026
Risk of herpes zoster among breast cancer survivors in Japan...
September 11,2026
Three proteins help organs tailor shared circadian clock to ...
September 10,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Can a twice-a-year shot help end the HIV...
Announcement of the 2025 Nobel Prize in ...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
More News
Myogenes identified for spondyloarthritis synovitis

Myogenes identified for spondyloarthritis synovitis

There are disease-specific and inflammation-independent stromal alterations in spondyloarthritis synovitis, according to a study published online Sept. 12 inArthritis & Rheumatism.(HealthDay
Immunology & Rheumatology April 08,2024
Myogenes identified for spondyloarthritis synovitis

Myogenes identified for spondyloarthritis synovitis

There are disease-specific and inflammation-independent stromal alterations in spondyloarthritis synovitis, according to a study published online Sept. 12 inArthritis & Rheumatism.(HealthDay
Immunology & Rheumatology April 08,2024
Study compares hospitalized infection risk for biologics in RA

Study compares hospitalized infection risk for biologics in RA

(HealthDay)—For patients with rheumatoid arthritis (RA) with prior biologic exposure, the risk of hospitalized infection is increased with etanercept, infliximab, and rituximab versus abatacept, accor
Immunology & Rheumatology April 08,2024
Study compares hospitalized infection risk for biologics in RA

Study compares hospitalized infection risk for biologics in RA

(HealthDay)—For patients with rheumatoid arthritis (RA) with prior biologic exposure, the risk of hospitalized infection is increased with etanercept, infliximab, and rituximab versus abatacept, accor
Immunology & Rheumatology April 08,2024
Rituximab retreatment at clinical relapse cost-effective in RA

Rituximab retreatment at clinical relapse cost-effective in RA

(HealthDay)—Rituximab retreatment at clinical relapse is at least as cost-effective as a more intensive regimen in longstanding rheumatoid arthritis (RA), according to a study published in the July is
Immunology & Rheumatology April 08,2024
Rituximab retreatment at clinical relapse cost-effective in RA

Rituximab retreatment at clinical relapse cost-effective in RA

(HealthDay)—Rituximab retreatment at clinical relapse is at least as cost-effective as a more intensive regimen in longstanding rheumatoid arthritis (RA), according to a study published in the July is
Immunology & Rheumatology April 08,2024
Innovative software improves chronic rheumatic disease care

Innovative software improves chronic rheumatic disease care

(HealthDay)—For patients with chronic rheumatic disease, innovative software that aggregates, stores, and displays information can improve quality of care, according to research published online Nov.
Immunology & Rheumatology April 08,2024
Innovative software improves chronic rheumatic disease care

Innovative software improves chronic rheumatic disease care

(HealthDay)—For patients with chronic rheumatic disease, innovative software that aggregates, stores, and displays information can improve quality of care, according to research published online Nov.
Immunology & Rheumatology April 08,2024
Combined inhibition of TNF-alpha, IL-17 effective in RA model

Combined inhibition of TNF-alpha, IL-17 effective in RA model

(HealthDay)—Combined inhibition of tumor necrosis factor (TNF) α and interleukin (IL)-17 is more effective than single blockade in cultures of human fibroblast-like synoviocytes (FLS), according to an
Immunology & Rheumatology April 08,2024
Combined inhibition of TNF-alpha, IL-17 effective in RA model

Combined inhibition of TNF-alpha, IL-17 effective in RA model

(HealthDay)—Combined inhibition of tumor necrosis factor (TNF) α and interleukin (IL)-17 is more effective than single blockade in cultures of human fibroblast-like synoviocytes (FLS), according to an
Immunology & Rheumatology April 08,2024
Brain activity linked to TNF inhibitor response in RA

Brain activity linked to TNF inhibitor response in RA

Patients with rheumatoid arthritis who respond to tumor necrosis factor inhibitors show changes in activity in pain-related areas of the brain before clinical signs of improvement are observed, accord
Immunology & Rheumatology April 08,2024
Brain activity linked to TNF inhibitor response in RA

Brain activity linked to TNF inhibitor response in RA

Patients with rheumatoid arthritis who respond to tumor necrosis factor inhibitors show changes in activity in pain-related areas of the brain before clinical signs of improvement are observed, accord
Immunology & Rheumatology April 08,2024
Gender, high DAS28-P index predictive of pain in early RA

Gender, high DAS28-P index predictive of pain in early RA

(HealthDay) -- For patients with rheumatoid arthritis (RA), female gender and having a high proportion of disease activity score (DAS28) attributable to patient-reported components (joint tenderness a
Immunology & Rheumatology April 08,2024
Gender, high DAS28-P index predictive of pain in early RA

Gender, high DAS28-P index predictive of pain in early RA

(HealthDay) -- For patients with rheumatoid arthritis (RA), female gender and having a high proportion of disease activity score (DAS28) attributable to patient-reported components (joint tenderness a
Immunology & Rheumatology April 08,2024
Patient-Rated elbow evaluation most responsive instrument

Patient-Rated elbow evaluation most responsive instrument

The Patient-Rated Elbow Evaluation form is the most responsive instrument to identify and quantify elbow joint-specific changes before and after total elbow arthroplasty, according to a study publishe
Immunology & Rheumatology April 08,2024
Patient-Rated elbow evaluation most responsive instrument

Patient-Rated elbow evaluation most responsive instrument

The Patient-Rated Elbow Evaluation form is the most responsive instrument to identify and quantify elbow joint-specific changes before and after total elbow arthroplasty, according to a study publishe
Immunology & Rheumatology April 08,2024
TNF inhibitors may not modify polyarticular JIA disease process

TNF inhibitors may not modify polyarticular JIA disease process

(HealthDay)—For children with polyarticular juvenile idiopathic arthritis (JIA), discontinuing medications is challenging, with high relapse rates, especially after discontinuation of tumor necrosis f
Immunology & Rheumatology April 08,2024
TNF inhibitors may not modify polyarticular JIA disease process

TNF inhibitors may not modify polyarticular JIA disease process

(HealthDay)—For children with polyarticular juvenile idiopathic arthritis (JIA), discontinuing medications is challenging, with high relapse rates, especially after discontinuation of tumor necrosis f
Immunology & Rheumatology April 08,2024
Increased insulin resistance in rheumatoid arthritis

Increased insulin resistance in rheumatoid arthritis

(HealthDay)—Patients with rheumatoid arthritis (RA) have elevated insulin resistance (IR), but this is not associated with increased atherosclerosis risk, according to a study published online Dec. 10
Immunology & Rheumatology April 08,2024
Increased insulin resistance in rheumatoid arthritis

Increased insulin resistance in rheumatoid arthritis

(HealthDay)—Patients with rheumatoid arthritis (RA) have elevated insulin resistance (IR), but this is not associated with increased atherosclerosis risk, according to a study published online Dec. 10
Immunology & Rheumatology April 08,2024
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com